1,800 Shares in C.R. Bard, Inc. (BCR) Acquired by 1832 Asset Management L.P.

1832 Asset Management L.P. acquired a new stake in C.R. Bard, Inc. (NYSE:BCR) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,800 shares of the company’s stock, valued at approximately $404,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BlackRock Institutional Trust Company N.A. boosted its position in C.R. Bard by 4.6% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 2,519,377 shares of the company’s stock valued at $565,046,000 after buying an additional 109,659 shares in the last quarter. BlackRock Fund Advisors boosted its stake in C.R. Bard by 1.7% in the third quarter. BlackRock Fund Advisors now owns 2,212,117 shares of the company’s stock worth $496,134,000 after buying an additional 36,622 shares during the last quarter. Standard Life Investments LTD boosted its stake in C.R. Bard by 27.4% in the third quarter. Standard Life Investments LTD now owns 1,309,071 shares of the company’s stock worth $293,565,000 after buying an additional 281,458 shares during the last quarter. Principal Financial Group Inc. boosted its stake in C.R. Bard by 1.4% in the third quarter. Principal Financial Group Inc. now owns 1,212,144 shares of the company’s stock worth $271,860,000 after buying an additional 16,780 shares during the last quarter. Finally, BlackRock Group LTD boosted its stake in C.R. Bard by 5.4% in the third quarter. BlackRock Group LTD now owns 1,044,476 shares of the company’s stock worth $234,257,000 after buying an additional 53,299 shares during the last quarter. 87.46% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

C.R. Bard, Inc. (NYSE:BCR) traded up 0.18% on Friday, hitting $240.29. The stock had a trading volume of 885,238 shares. The company has a market cap of $17.67 billion, a P/E ratio of 34.18 and a beta of 0.63. The stock’s 50-day moving average is $232.33 and its 200-day moving average is $222.27. C.R. Bard, Inc. has a 52-week low of $184.59 and a 52-week high of $241.50.

C.R. Bard (NYSE:BCR) last released its earnings results on Thursday, January 26th. The company reported $2.77 EPS for the quarter, beating the Zacks’ consensus estimate of $2.74 by $0.03. The business had revenue of $967.10 million for the quarter, compared to analysts’ expectations of $956.12 million. C.R. Bard had a return on equity of 48.48% and a net margin of 14.31%. The firm’s revenue was up 10.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.43 earnings per share. Analysts expect that C.R. Bard, Inc. will post $11.64 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, February 3rd. Investors of record on Monday, January 23rd were paid a $0.26 dividend. The ex-dividend date of this dividend was Thursday, January 19th. This represents a $1.04 dividend on an annualized basis and a yield of 0.43%. C.R. Bard’s dividend payout ratio is presently 14.77%.

ILLEGAL ACTIVITY WARNING: “1,800 Shares in C.R. Bard, Inc. (BCR) Acquired by 1832 Asset Management L.P.” was originally reported by sleekmoney and is owned by of sleekmoney. If you are accessing this news story on another site, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be read at http://sleekmoney.com/1800-shares-in-c-r-bard-inc-bcr-acquired-by-1832-asset-management-l-p/1656964.html.

A number of analysts have recently issued reports on BCR shares. Morgan Stanley raised C.R. Bard from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $240.00 to $260.00 in a research report on Tuesday, January 3rd. Zacks Investment Research upgraded C.R. Bard from a “hold” rating to a “buy” rating and set a $241.00 price objective on the stock in a research note on Thursday, October 27th. BMO Capital Markets upgraded C.R. Bard from a “market perform” rating to an “outperform” rating and set a $240.00 price objective on the stock in a research note on Wednesday, October 26th. They noted that the move was a valuation call. Barclays PLC restated a “hold” rating and set a $245.00 price objective on shares of C.R. Bard in a research note on Sunday, January 29th. Finally, Raymond James Financial, Inc. upgraded C.R. Bard from an “outperform” rating to a “strong-buy” rating and raised their price objective for the stock from $250.00 to $265.00 in a research note on Thursday, January 5th. Eight equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $244.14.

In other C.R. Bard news, VP John A. Deford sold 5,816 shares of the company’s stock in a transaction dated Thursday, February 9th. The shares were sold at an average price of $239.58, for a total transaction of $1,393,397.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jim C. Beasley sold 8,593 shares of the company’s stock in a transaction dated Thursday, February 9th. The shares were sold at an average price of $239.58, for a total transaction of $2,058,710.94. Following the sale, the insider now owns 34,415 shares of the company’s stock, valued at $8,245,145.70. The disclosure for this sale can be found here. In the last three months, insiders sold 91,128 shares of company stock worth $21,043,269. 0.97% of the stock is owned by insiders.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.

5 Day Chart for NYSE:BCR

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/1800-shares-in-c-r-bard-inc-bcr-acquired-by-1832-asset-management-l-p/1656964.html

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *